• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
The Egyptian Journal of Hospital Medicine
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 99 (2025)
Volume Volume 98 (2025)
Volume Volume 97 (2024)
Issue Issue 1
Volume Volume 96 (2024)
Volume Volume 95 (2024)
Volume Volume 94 (2024)
Volume Volume 93 (2023)
Volume Volume 92 (2023)
Volume Volume 91 (2023)
Volume Volume 90 (2023)
Volume Volume 89 (2022)
Volume Volume 88 (2022)
Volume Volume 87 (2022)
Volume Volume 86 (2022)
Volume Volume 85 (2021)
Volume Volume 84 (2021)
Volume Volume 83 (2021)
Volume Volume 82 (2021)
Volume Volume 81 (2020)
Volume Volume 80 (2020)
Volume Volume 79 (2020)
Volume Volume 78 (2020)
Volume Volume 77 (2019)
Volume Volume 76 (2019)
Volume Volume 75 (2019)
Volume Volume 74 (2019)
Volume Volume 73 (2018)
Volume Volume 72 (2018)
Volume Volume 71 (2018)
Volume Volume 70 (2018)
Volume Volume 69 (2017)
Volume Volume 68 (2017)
Volume Volume 67 (2017)
Volume Volume 66 (2017)
Volume Volume 65 (2016)
Volume Volume 64 (2016)
Volume Volume 63 (2016)
Volume Volume 62 (2016)
Volume Volume 61 (2015)
Volume Volume 60 (2015)
Volume Volume 59 (2015)
Volume Volume 58 (2015)
Volume Volume 57 (2014)
Volume Volume 56 (2014)
Volume Volume 55 (2014)
Volume Volume 54 (2014)
Volume Volume 53 (2013)
Volume Volume 52 (2013)
Volume Volume 51 (2013)
Volume Volume 50 (2013)
Volume Volume 49 (2012)
Volume Volume 48 (2012)
Volume Volume 47 (2012)
Volume Volume 46 (2012)
Volume Volume 45 (2011)
Volume Volume 44 (2011)
Volume Volume 43 (2011)
Volume Volume 42 (2011)
Volume Volume 41 (2010)
Volume Volume 40 (2010)
Volume Volume 39 (2010)
Volume Volume 38 (2010)
Volume Volume 37 (2009)
Volume Volume 36 (2009)
Volume Volume 35 (2009)
Volume Volume 34 (2009)
Volume Volume 33 (2008)
Volume Volume 32 (2008)
Volume Volume 31 (2008)
Volume Volume 30 (2008)
Volume Volume 29 (2007)
Volume Volume 28 (2007)
Volume Volume 27 (2007)
Volume Volume 26 (2007)
Volume Volume 25 (2006)
Volume Volume 24 (2006)
Volume Volume 23 (2006)
Volume Volume 22 (2006)
Volume Volume 21 (2005)
Volume Volume 20 (2005)
Volume Volume 19 (2005)
Volume Volume 18 (2005)
Volume Volume 17 (2004)
Volume Volume 16 (2004)
Volume Volume 15 (2004)
Volume Volume 14 (2004)
Volume Volume 13 (2003)
Volume Volume 12 (2003)
Volume Volume 11 (2003)
Volume Volume 10 (2003)
Volume Volume 9 (2002)
Volume Volume 8 (2002)
Volume Volume 7 (2002)
Volume Volume 6 (2002)
Volume Volume 5 (2001)
Volume Volume 4 (2001)
Volume Volume 3 (2001)
Volume Volume 2 (2001)
Volume Volume 1 (2000)
(2024). PI3K / AKT / GSK-3β Pathway Mediates the Ameliorative Effect of Amentoflavone on Hepatorenal Injury Induced by Doxorubicin. The Egyptian Journal of Hospital Medicine, 97(1), 3688-3693. doi: 10.21608/ejhm.2024.387337
. "PI3K / AKT / GSK-3β Pathway Mediates the Ameliorative Effect of Amentoflavone on Hepatorenal Injury Induced by Doxorubicin". The Egyptian Journal of Hospital Medicine, 97, 1, 2024, 3688-3693. doi: 10.21608/ejhm.2024.387337
(2024). 'PI3K / AKT / GSK-3β Pathway Mediates the Ameliorative Effect of Amentoflavone on Hepatorenal Injury Induced by Doxorubicin', The Egyptian Journal of Hospital Medicine, 97(1), pp. 3688-3693. doi: 10.21608/ejhm.2024.387337
PI3K / AKT / GSK-3β Pathway Mediates the Ameliorative Effect of Amentoflavone on Hepatorenal Injury Induced by Doxorubicin. The Egyptian Journal of Hospital Medicine, 2024; 97(1): 3688-3693. doi: 10.21608/ejhm.2024.387337

PI3K / AKT / GSK-3β Pathway Mediates the Ameliorative Effect of Amentoflavone on Hepatorenal Injury Induced by Doxorubicin

Article 40, Volume 97, Issue 1, October 2024, Page 3688-3693  XML PDF (708.04 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2024.387337
View on SCiNiTO View on SCiNiTO
Abstract
Background: Doxorubicin (DOX) induced hepatorenal injury is a major health concern. Amentoflavone (AMF) is a biflavonoid with conspicuous pharmacological activities.
Objective: To clarify the possible protective AMF effect on DOX associated hepatorenal injury & the possible underlying mechanisms.
Material and methods: 30 rats were equally divided to three groups: control group. DOX group and DOX+AMF treated. After that blood samples were withdrawn for assessment of serum urea, creatinine, ALT, AST, MDA, TNF-α, caspase-3, SOD and IL10. Liver and kidney were preserved for AKT, PI3K and GSK-3β genes expression level detection. Finally, Histopathological assessment of hepatic and renal section was done.
Results: DOX group revealed a significant increase in urea, creatinine, ALT, AST, MDA, TNF-α, and caspase-3, along with a concurrent decrease in SOD and IL10 when compared to control rats. Serum levels of urea, creatinine, ALT, AST, MDA, TNF-α, caspase3 were significantly reduced, and SOD and IL10 were significantly increased in the DOX+AMF group compared to DOX group, while there was a significant reduction in the expression of the AKT and PI3K genes and a concurrent increase in the expression of the GSK-3β gene with DOX treatment. AMF significantly mitigated the expression of the AKT and PI3K genes with reduction of GSK-3β gene after 8 weeks.
Conclusion: AMF protects against doxorubicin induced hepatorenal injury by antioxidant, anti-inflammatory, anti-apoptotic mechanisms in addition to modulation in PI3K/AKT/GSK-3β signaling pathway.
 
Keywords
Amentoflavone; AKT; Doxorubicin; GSK-3β; PI3K; Hepatorenal injury
Statistics
Article View: 155
PDF Download: 127
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.